BioWorld Asia

Oct. 13, 2010

Synosia Therapeutics Nabs Potential $725M Pact with UCB

LONDON – Synosia Therapeutics sealed a $725 million pact on its two lead drugs for treating Parkinson's disease with UCB Pharma, and announced the closing of a third round funding of $30 million. (BioWorld International) Read More

Morphosys Pairs Antibody Platform with Sloning's

Optical Stimulation Shines New Light on Heart Muscle Cells

Ablynx Expands Merck Deal for Nanobody Technology

Diagenic Gets $12M for New Biomarker Strategy

Biotech Foundations: Biotech VC Larry Bock Uses Start-up Spirit in Science Fest

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2026.

Depression concept with human, broken brain and heavy rain

CROI 2026 highlights depression and cognitive vulnerability in HIV

BioWorld

The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

University of Southern California reports new MAPT aggregation inhibitors

BioWorld Science

The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...